Awards: Marangoni Award of the Maggiore Hospital of Milan for scientific merit (1985). The abstract "In vitro and in vivo evaluation of the hematopoietic potential of human muscle cells." has been awarded as the best 2001 scientific presentation either at the European Hematology Association (EHA) meeting in Frankfurt and at the Italian Society of Hematology (SIE) meeting in Florence.
Current interests: in vitro and in vivo models of hematopoiesis, angiogenesis and angiogenesis inhibitors in animal models of hematopoietic neoplastic diseases. Autologous and allogeneic transplantation of hematopoietic stem cells.
Other fields of interests: cytokine-mediated mobilization of stem cells into peripheral blood, stem cell expansion and gene transfer into hematopoietic progenitor cells. Platelet transfusion, leuko-depletion of blood components.
1981-1986: Medical student in the blood research section and in the laboratory of immunology at the Blood Transfusion and Transplant Immunology Institute (Centro Trasfusionale e di Immunologia dei Trapianti), of the Milan University Hospital (Ospedale Maggiore Policlinico).
1989-1990: Visiting Research Scientist, Cardeza Foundation for Hematological Research, Thomas Jefferson University, Philadelphia, USA. Laboratory of Scott Murphy, MD.
1989-1995: Medical assistant, Blood Transfusion and Transplant Immunology Institute, Department of Hematology, Ospedale Maggiore Policlinico, Milan.
Since 1992, head of the stem cell laboratory devoted to stem cell collection from umbilical cord blood as part of the European Cord Blood Bank Project.
1995-1998: Vice-Director and Head of the Experimental Hematology-Oncology Lab, Division of Medical Oncology, Scientific Institute Maugeri Foundation, Pavia Medical Center, Pavia.
1998-onward: Director (formerly Vice-Director, 1998-2000, and Co-Director, 2001-2005) Division of Laboratory of Hematology-Oncology, European Institute of Oncology, Milan.
1992-96: Instructor of Laboratory Medicine at the University of Milan. 1992-onward: Teacher of the post-graduate Medical School of Oncology, Internal Medicine, Hematology and Radiololgy at the University of Milan. 2009-onward, teacher at the Advanced Breast Cancer Research Course, University of Milan. 2009-onward: teacher at the Faculty of Biology, University of Milan.
2008-onward: Faculty member, the European School of Molecular Medicine (SEMM, Milan) PhD program.
2013: Enabled as Associate Professor of Hematology-Oncology
2014: Enabled as Full (Ordinary) Professor of General and Clinical Pathology
2014: Enabled as Full (Ordinary) Professor of Medical Technologies
2011-onward: Member of the Health Technology Assessment Board of Regione Lombardia (Lombardy section of the Italian National Health System)
Member of the Editorial Board, PLOS ONE, Cancer Reports, Ecancermedicalscience, Clinical cancer Drugs, European Journal of Clinical and Medical Oncology.
Referee for Nature, PNAS, Lancet Oncology, Journal of Clinical Investigation, Journal of the National Cancer Institute, Journal of Clinical Oncology, Nature Reviews in Clinical Oncology, Blood, Cancer Research, Clinical Cancer Research, BBA-Reviews on Cancer, Molecular Cancer, Molecular Cancer Research, Experimental Hematology, FASEB Journal, Annals of Oncology, Differentiation, Leukemia, Stem Cells, Annals of Oncology, PLOS ONE, Neoplasia, Thrombosis and Haemostasis, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Cancer Letters, Carcinogenesis, Molecular Cancer, Medicinal Research Reviews, Journal of Cellular and Molecular Medicine, BMC Cancer, BMC Gastroenterology, British Journal of Haematology, Angiogenesis, Investigational New Drugs, Expert Opinion on Therapeutic Targets, Human Immunology, Cell Proliferation, Cancer Biology and Therapy, Molecular Cancer Research, Molecular Cancer, New Drugs and Perspectives, Hematological Oncology, Journal of Cancer Research and Clinical Oncology, European Journal of Hematology, Annals of Hematology, Advances in Hematology, European Journal of Internal Medicine, Future Oncology, European Journal of Cancer Prevention, Journal of Laboratory and Clinical Medicine, Neurosurgery, Vox Sanguinins, Haematologica, Advances in Therapy.
Abstract reviewer for the meetings of the American Society of Hematology (2005) and the European Hematology Association (2008).
Reviewer for the European Research Counsil (ERC), the European Commission in the 6th and 7th Framework Programmes, the Health Research Board of the republic of Ireland, the Israel Science Foundation, the German-Israeli Foundation and for the University of Vienna.
Consultant of the the Spanish Ministry of Health and Consumer's Affairs in the national program of cooperative research aiming to integrate research from basic and clinical groups.
Consultant of the French national Cancer Institute for the review of grant applications.
Consultant of the Polish national Cancer Institute for the review of grant applications.
Consultant of the Swiss Cancer League for the review of grant applications.
Consultant for hematopoietic stem cell transplant for the Italian National Institute of Health.
Since 1996: Scholar of the National Blood Foundation of the American Association of Blood Banks.
Member of the Board: European Union Concerted Action Eurocord, Immunobiology Working Party of the EBMT (European Group for Blood and Marrow Transplantation), European School of Transfusion Medicine, Cord Blood Committee of the International Society of Hematotherapy and Graft Engineering (ISHAGE), European Cord Blood Bank.
1993-1995: Project 325 Finished Research Lombardia Region "Innovative Methods for the preparation of platelet concentrates", Italian Pounds 100.000.000
1996: National Blood Foundation, USA. "Ex vivo expansion of hemopoietic progenitors collected from cord blood", US $ 26,200
1997-2000: European Union Concerted Action "European research on cord blood bank and use for transplantation", subcommittee on ex vivo expansion and gene therapy, ECU 150.000
1997: Medsep (a subsidiary of Pall Group, USA): Studies on cord blood collection and storage, US $ 29,000
1997: Rhone-Poulenc Rorer Italia: Effect of Docetaxel on human hematopoietic stem cells. Lire 25.000.000
1997-1999: Fondazione San Paolo, Torino: Project CONESTRO for collection, expansion and transplant of hematopoietic stem cells. Lire 1.550.000.000
1998: Medsep (a subsidiary of Pall Group, USA): Studies on cord blood collection and processing, US $ 20,000.
1998-2000: AIRC (Italian foundation for Cancer Research): Studies on CD34 negative hematopoietic stem cells, Lire 70.000.000/year
2000-2001: Entremed, Rockville, USA. Studies on Endostatin and angiostatin in hematopoietic malignancies. US $ 45,500.
2001-2004: AIRC (Italian foundation for Cancer Research): Endothelial cells as nursing cells in hematopoietic malignancies. L 90.000.000/year.
2002-2003: Agouron-Pfizer, La Jolla, USA. In vitro and in vivo studies on AG13736. US $ 82,000.
2003-2004: Bristol-Myers-Squibb, USA: In vitro and in vivo studies on BMS-582664. US $ 158,500.
2004-2005: Pfizer, USA: CEC in animal models € 150,000
2004: Entremed, USA: 2ME2 in hematological malignancies, US $ 50,000
2004-2005: Istituto Superiore di Sanità (Italian NIH): Endothelial stem cells, gene expression, vasculogenesis and cancer growth, € 90,000.
2004-2007: 6th EU Framework Programme: Integrated Project "Angiotargeting", total funding 6 million € (FB is a member of the IP executive committee).
2004-2006: AIRC (Italian foundation for Cancer Research): Molecular and cellular determinants of preclinical and clinical response to anti-angiogenic drugs. € 65.000/year.
2005-6: DAC Srl (Milano): Pre-clinical investigation of endostatin peptides in preclinical cancer models. € 50,000.
2005-6: Pfizer, USA: Investigation of novel receptors on CEC surface. US $ 22,000
2006: Pfizer, USA: CEC enumeration in clinical trials, euro 30-94,000
2007-9: Pfizer, USA: Sutent and the cancer stem cell niche in metastatic kidney cancer. US $ 150,000
2007: Pfizer, USA: Standardization of CEC measurement. US $ 62,500
2007: Pfizer, USA: S1P1 expression in CEC. US $ 42,000
2007-2008: Istituto Superiore di Sanità (Italian NIH): Development of novel molecular approaches for the diagnosis and characterization of genetic lymphedema, € 110,000.
2007-2009: Italian Ministry of Health. The role of endothelial progenitors in cancer, € 100,000.
2007-2009: Alleanza contro il Cancro. Sviluppo di nuovi farmaci capaci di alterare il microambiente tumorale e di ripristinare la risposta immune anti-tumorale. € 60,000.
2007-2009: Italian Ministry of Health. Surrogate markers of angiogenesis in triple receptor-negative breast cancer patients. € 75,000.
2007-2010: Italian Ministry of Health. Neoangiogenesis in hepatoma and other tumors: novel therapeutical targeting of endothelial precursors. € 100,000.
2008: Pfizer, USA. Development of circulating endothelial cell analytical methodologies for canine samples. US $ 10,000.
2008: Pfizer, USA. Laboratory services to evaluate a new Pfizer drug in a clinical study. € 155,250.
2007-2009: AIRC (Italian Foundation for Cancer Research): Marker-driven, patient-tailored optimization of the chemosensitizing effect of anti-angiogenic drugs. € 140.000/year.
2008-2011: Italian Ministry of Health, Progetto Integrato Oncologia, "Cancer stem cells, drug resistance and niche in minimal residual disease". € 80,000.
2008-2009: Italian Ministry of Health: "A two-step protocol for infarcted myocardium repair by engineered bone marrow progenitors and cardiac mesangioblasts ". € 163,000
2009: Tethis: “Microfluids for FISH”. € 25,000.
2010: Università di Padova: Assessment of the circulating endothelial cells in diabetes. € 25,200.
2010: Molmed: Study of circulating perivascular progenitors and circulating lympho-endothelial progenitors (CLEP) as possible targets of NGR-TNF and rGn peptide. € 85,000
2010-12: Umberto Veronesi Foundation: Circulating tumor cells and mutated DNA in breast and colo-rectal cancer. € 150,000.
2011-2: Pfizer, USA: Anti-ALK1 in preclinical models of NHL. € 50,000.
2010-2013: AIRC (Italian Foundation for Cancer Research): From resistance to anti-VEGF drugs to “next generation” anti-angiogenic therapies of cancer. € 250.000/year.
2011-2: EOS: First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. CEC and CVEP enumeration. € 50,000
2011-13 Italian Ministry of Health, Finalized Research: “Biomarker‐driven development of 3rd generation antiangiogenic cancer therapies” € 289,333
2012-3: Pfizer, USA: Anti-ALK1 in precliical models of HCC. € 50,000.
2013-2014: Umberto Veronesi Foundation: Genomics of treatment response in AML patients over 60. € 130,000.
2014-2016: AIRC (Italian Foundation for Cancer Research): Targeting adipose cell contribution to breast cancer angiogenesis, local and metastatic growth. € 245,000/year
POST-DOCTORAL STUDENTS- TRAINEES: 32 in total
PEER REVIEWED PAPERS
As of September 1st, 2014: 170 peer reviewed papers, >7900 citations, h-index 47(Web of Science).
Three papers (FB always first or last author) have >300 citations, 8 papers (5 out of 8 with FB first or senior author) have >200 citations, 17 (11 out of 17 with FB first or senior author) have >100 citations.